PMID: 15232360Jul 3, 2004Paper

Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects

Journal of Clinical Gastroenterology
S I HarrisR C Hubbard

Abstract

The gastrointestinal safety of the novel injectable cyclooxygenase-2 selective inhibitor, parecoxib sodium, was compared with the nonselective nonsteroidal anti-inflammatory drug, ketorolac, and placebo in healthy subjects. In a multicenter, randomized, double-blind, placebo-controlled design, 123 adults with endoscopically-confirmed normal upper gastrointestinal mucosae received parecoxib sodium 40 mg twice daily (7 days); placebo (2 days) followed by ketorolac 30 mg 4 times daily (5 days); or placebo (7 days) (each group n = 41). Posttreatment endoscopy scores were analyzed at 3 levels of severity: ulcers (scores of 7), > or =11 erosions/ulcers (scores of 5-7), and any erosions/ulcers (scores of 3-7). No subjects treated with parecoxib sodium or placebo developed gastroduodenal ulcers or > or =11 erosions/ulcers. Parecoxib sodium was comparable to placebo with respect to the combined incidence of erosions/ulcers (12% vs. 7%, P = 0.419). In contrast, in the ketorolac group, 11 (28%) subjects developed ulcers, 19 (48%) subjects developed > or =11 gastroduodenal erosions/ulcers, and the rate of combined ulcers/erosions was 85% (P < 0.001 vs. placebo and parecoxib sodium). Parecoxib sodium 40 mg twice daily for 7 days has a gastr...Continue Reading

Associated Clinical Trials

References

Jun 13, 1991·The New England Journal of Medicine·P M Brooks, R O Day
Dec 2, 1999·JAMA : the Journal of the American Medical Association·L S SimonG S Geis
Jul 6, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D I Reinhart
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Jan 26, 2002·The American Journal of Gastroenterology·Randall R StoltzRichard C Hubbard

❮ Previous
Next ❯

Citations

Dec 12, 2003·Lancet·Henrik Kehlet, Jørgen B Dahl
Feb 8, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Maria Cristina ColanardiAngelo Vacca
Sep 3, 2017·BMJ Supportive & Palliative Care·Peter ArmstrongNoleen K McCorry
Sep 8, 2018·JAMA Otolaryngology-- Head & Neck Surgery·Ryan J LiJason Y K Chan
Jun 21, 2006·Journal of Cardiovascular Pharmacology·Stephan A Schug
Feb 4, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jørgen Naesdal, Kurt Brown
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Rosalind LloydHenry J McQuay
Oct 19, 2013·Experimental and Therapeutic Medicine·Wei WeiYuantao Li

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Acta Anaesthesiologica Taiwanica : Official Journal of the Taiwan Society of Anesthesiologists
John On-Nin WongMary Paul Watts
The Annals of Pharmacotherapy
Celene M Amabile, Anne P Spencer
The American Journal of Gastroenterology
Randall R StoltzR C Hubbard
International Braz J Urol : Official Journal of the Brazilian Society of Urology
Sidney GlinaGaston Araya
© 2022 Meta ULC. All rights reserved